HC Wainwright Issues Optimistic Outlook for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities researchers at HC Wainwright raised their Q2 2026 EPS estimates for Unicycive Therapeutics in a research note issued on Wednesday, May 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.27) per share for the quarter, up from their prior estimate of ($0.28). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.44) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($1.04) EPS, Q1 2027 earnings at $0.26 EPS, Q2 2027 earnings at $0.35 EPS, Q3 2027 earnings at $0.46 EPS and Q4 2027 earnings at $0.51 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.08).

Several other equities analysts have also issued reports on the stock. Wall Street Zen lowered shares of Unicycive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd. Westpark Capital started coverage on shares of Unicycive Therapeutics in a report on Thursday, February 19th. They issued a “buy” rating on the stock. Benchmark dropped their target price on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating on the stock in a report on Monday, April 6th. Guggenheim restated a “buy” rating and issued a $37.00 target price (down from $40.00) on shares of Unicycive Therapeutics in a report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, March 27th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Unicycive Therapeutics Stock Performance

Shares of NASDAQ:UNCY opened at $8.56 on Friday. The firm has a market cap of $228.55 million, a PE ratio of -3.87 and a beta of 1.78. The firm’s fifty day moving average is $7.10 and its 200-day moving average is $6.38. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $11.00.

Institutional Investors Weigh In On Unicycive Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp increased its stake in Unicycive Therapeutics by 19.0% in the fourth quarter. State Street Corp now owns 65,227 shares of the company’s stock valued at $376,000 after purchasing an additional 10,400 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Unicycive Therapeutics in the second quarter valued at $55,000. JPMorgan Chase & Co. increased its stake in Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after purchasing an additional 21,525 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Unicycive Therapeutics in the first quarter valued at $161,000. Finally, Quadrature Capital Ltd bought a new stake in Unicycive Therapeutics in the fourth quarter valued at $226,000. 40.42% of the stock is owned by institutional investors.

Trending Headlines about Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Noble Financial raised its FY2026 EPS estimate to $1.46 from $0.85 and boosted its Q3 2026 view to $1.32 from $0.79, suggesting improved longer-term profitability expectations.
• Positive Sentiment: HC Wainwright slightly improved its Q2 2026 EPS estimate to ($0.27) from ($0.28), and trimmed its Q4 2026 loss estimate to ($0.03) from ($0.12), indicating a modestly better near-term outlook.
• Positive Sentiment: HC Wainwright also lifted its Q1 2027, Q2 2027, Q3 2027, and Q4 2027 EPS estimates, pointing to stronger profitability later in the forecast period.
• Neutral Sentiment: Analyst reports from HC Wainwright and Noble Financial updated multiple quarterly earnings estimates for UNCY, but the company’s consensus full-year outlook remains a loss at ($1.44) per share.
• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to ($1.04) from ($0.90), implying a larger expected loss for the current year. HC Wainwright FY2026 estimate cut
• Negative Sentiment: Noble Financial lowered its Q2 2026 EPS estimate to ($0.77) from ($0.52), and HC Wainwright cut its Q3 2026 estimate to ($0.20) from ($0.16), reinforcing some near-term pressure on earnings expectations.
• Negative Sentiment: Separate headlines noted a reduced price target and a “pivots from profit to loss” narrative, which could contribute to bearish sentiment around the stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.